Gilead Sciences, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Daniel O'Day
- Full Time Employees
- 17,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 333 Lakeside Drive Foster City CA United States of America 94404
- IPO Date
- Jan 22, 1992
- CIK
- 0000882095
- Website
- gilead.com
- Similar Companies
- Business
- Gilead Sciences, Inc. (Nasdaq: GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need, with primary focus areas including HIV/AIDS, viral hepatitis, oncology, inflammation and serious respiratory diseases. The company markets a portfolio of marketed products such as Biktarvy, Descovy, Truvada and Veklury for virology; Epclusa, Vosevi and Vemlidy for liver diseases; Trodelvy, Tecartus and Yescarta for oncology; and investigational assets across its therapeutic areas, including complete regimen single-tablet treatments for HIV, nucleotide reverse transcriptase inhibitors and NS5A/NS5B inhibitors for hepatitis C. Founded in 1987 and headquartered in Foster City, California, Gilead operates globally with facilities across North America, Europe (including international headquarters in Stockley Park, UK), Asia-Pacific (such as Japan, China and Australia) and approximately 17,000 employees worldwide. Recent strategic developments include a $32 billion U.S. investment commitment by 2030 to expand manufacturing and R&D capabilities, highlighted by the September 2025 groundbreaking of a new Pharmaceutical Development and Manufacturing Technical Development Center in Foster City projected to create thousands of jobs; an up-to-$400 million acquisition in November 2025 of Sprint Bioscience's preclinical TREX1 oncology immunotherapy program; a $350 million buyout in August 2025 of Interius BioTherapeutics by subsidiary Kite Pharma to advance in vivo CAR-T cell therapies for cancer; a January 2025 strategic partnership with LEO Pharma acquiring rights to preclinical oral STAT6 inhibitors and targeted protein degraders for inflammatory diseases; and an expanded agreement with Cognizant in early 2025 to enhance productivity through advanced technologies.
Company News
Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments
Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying
Gilead Sciences, Inc. $GILD Stock Acquired by RHS Financial LLC
Which Pharmaceuticals ETF Is the Better Buy: iShares’ IHE or Invesco’s PJP?
Head to Head Contrast: Gilead Sciences (NASDAQ:GILD) vs. GRAIL (NASDAQ:GRAL)
Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma
Gilead Sciences (GILD) Laps the Stock Market: Here's Why
Gilead (NASDAQ: GILD) CEO sells 15,000 shares under a preset plan
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
More Upside Awaits for Gilead Sciences Stock. Stay Invested.
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors
Gilead Sciences, Inc. (NASDAQ:GILD) Stock Has Average Price Target of $158.78 According to Analysts
Genetic discovery yields clues toward reversal of Alzheimer's brain damage
NTHM's Index Rebalance Puts Thematic Rotation to Work
Gilead Sciences, Inc. $GILD Stake Decreased by Envestnet Asset Management Inc.
BMY vs GILD: Which Biotech Stock Looks More Attractive Now?
Latin America's PAHO-Gilead HIV Prevention Deal Is a Victory for Civil Society, says AHF
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Gilead Expands Lenacapavir Access With New PAHO Deal in Latin America